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Abstract 
Background: Dysglycaemia defined as type 2 diabetes (T2DM) and impaired glucose tolerance (IGT), increases the 
risk of cardiovascular disease (CVD). The negative impact is more apparent in the presence of hypertension and/or 
dyslipidaemia. Thus, it seems reasonable to screen for dysglycaemia in patients treated for hypertension and/or dys-
lipidaemia. A simple screening algorithm would enhance the adoption of such strategy in clinical practice.
Objectives: To test the hypotheses (1) that dysglycaemia is common in patients with hypertension and/or dyslipi-
daemia and (2) that initial screening with the Finnish Diabetes Risk Score (FINDRISC) will decrease the need for labora-
tory based tests.
Methods: 2395 patients (age 18–80 years) without (i) a history of CVD or TDM2, (ii) prescribed blood pressure and/or 
lipid lowering drugs answered the FINDRISC questionnaire and had an oral glucose tolerance test (OGTT) and HbA1c 
measured.
Results: According to the OGTT 934 (39%) had previously undetected dysglycaemia (T2DM 19%, IGT 20%). Of 
patients, who according to FINDRISC had a low, moderate or slightly elevated risk 20, 34 and 41% and of those in the 
high and very high-risk category 49 and 71% had IGT or T2DM respectively. The OGTT identified 92% of patients with 
T2DM, FPG + HbA1c 90%, FPG 80%, 2hPG 29% and HbA1c 22%.
Conclusions: (1) The prevalence of dysglycaemia was high in patients treated for hypertension and/or dyslipidaemia. 
(2) Due to the high proportion of dysglycaemia in patients with low to moderate FINDRISC risk scores its initial use did 
not decrease the need for subsequent glucose tests. (3) FPG was the best test for detecting T2DM. Its isolated use is 
limited by the inability to disclose IGT. A pragmatic strategy, decreasing the demand for an OGTT, would be to screen 
all patients with FPG followed by OGTT in patients with IFG.
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Introduction
Dysglycaemia, defined as type 2 diabetes (T2DM) or 
impaired glucose tolerance (IGT), is an important risk 
factor for cardiovascular disease (CVD), the common-
est cause of death globally [1]. Screening for dysglycae-
mia is performed by means of three blood tests: glycated 
haemoglobin A1c (HbA1c), fasting plasma glucose (FPG) 
and a 2  hour post load plasma glucose (2hPG), the lat-
ter only obtainable by means of an oral glucose tolerance 
test (OGTT) [2]. Several scoring systems for estimating 
the future risk of T2DM have been developed. One of 
them, the FINDRISC questionnaire, has been validated 
in several European populations. FINDRISC classifies the 
respondent as having a low, moderate, high or very high 
risk of developing T2DM during the forthcoming decade. 
If an individual is at a high or very high risk, an OGTT is 
recommended for further investigation [3].
Importantly, not only T2DM but also its preceding, 
hyperglycaemic state IGT increases the risk of CVD [4, 
5]. Other intermediate hyperglycaemic states include 
impaired fasting glucose (IFG) and “high-risk” glycated 
haemoglobin A1c (HbA1c). The Atherosclerosis Risk in 
Communities (ARIC) study reported that people with 
“high risk” HbA1c are at increased risk of developing dia-
betes and CVD independent of FPG [6], but a postload 
glucose was not included in this study. Other population 
based studies among them the Diabetes Epidemiology: 
Collaborative Analysis of Diagnostic Criteria in Europe 
(DECODE), a substudy of the DECODE population and 
the Framingham Offspring Study demonstrated that the 
2hPG is a significantly stronger predictor of future CVD 
and all-cause mortality than FPG and HbA1c [7–9]. Simi-
lar findings were recently presented from a large Euro-
pean population of patients with coronary artery disease 
[10].
Screening for dysglycaemia is encouraged by the fact 
that T2DM can be prevented or delayed by approxi-
mately 50% with lifestyle and/or pharmacological inter-
ventions [11–13]. Although advocated by contemporary 
guidelines systematic screening of high risk people is 
infrequently implemented [2]. A concern is therefore that 
large proportions of dysglycaemic individuals remain 
unrecognized, thereby deprived preventive opportunities.
This study tested the hypotheses that (1) if appropri-
ately screened the prevalence of dysglycaemia is high 
in patients free from CVD but treated for hypertension 
and/or dyslipidaemia, and (2) that initiating screening 
with the FINDRISC questionnaire would limit the need 
for more expensive and time consuming blood tests. 
These hypotheses were tested within the auspices of 
the European Action on Secondary Prevention through 
Intervention to Reduce Events-IV (EUROASPIRE-IV), a 
large cross-sectional survey.
Materials and methods
Study population
The primary care arm of EUROASPIRE IV was carried 
out in 14 European countries January 2014–April 2015 
(Bosnia and Herzegovina, Bulgaria, Croatia, Kazakhstan, 
Lithuania, Poland, Portugal, Romania, Russian Federa-
tion, Serbia, Spain, Sweden, Ukraine and the UK). Within 
each country one or more geographical areas with a 
defined population were selected. A sample of general 
practices serving that population was identified accord-
ing to the structure of the local health services.
Within each general practice men and women ≥ 18 to 
< 80 years at the time of identification, without a history 
of CVD, coronary or other atherosclerotic disease, who 
had been prescribed one or more of the following treat-
ments: (i) blood pressure lowering drugs and/or (ii) lipid 
lowering drugs and/or (iii) glucose lowering (diet and/or 
oral drugs and/or insulin) since ≥ 6 months to < 3 years 
prior to the date of interview, were retrospectively iden-
tified from practice records. The total number of such 
patients was 4579 of whom 1325 with a history of treat-
ment for diabetes and 42 who lacked information on dia-
betes were excluded. Out of the remaining 3212 patients 
the information on plasma glucose or HbA1c (n = 522) 
and the FINDRISC questionnaire (n = 295) was incom-
plete leaving 2395 as the study population (Fig. 1).
Methods
Centrally trained research staff undertook data collection 
using standardised methods and the same instruments in 
all centres. They reviewed patient medical records and 
interviewed and examined the patients at the general 
practice or home at least 6 months after the prescription 
of blood pressure, lipid or glucose lowering therapy. A 
detailed description of this procedure and applied defi-
nitions have been presented elsewhere [14]. Methods 
of particular relevance for the present investigation are 
described below.
Height (kg) and weight (cm) were recorded in light 
indoor clothes without shoes (Scales 701 and Measur-
ing stick model 220; SECA Medical Measuring Systems 
and Scales, Birmingham, UK). Waist circumference (cm) 
Keywords: Type 2 diabetes, Impaired glucose tolerance, Screening, FINDRISC, Dyslipidaemia, Hypertension, Primary 
care
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[15] was measured using a metal tape applied horizon-
tally at the point midway in the mid-axillary line between 
the lowest rim of the rib cage and the tip of the hip bone 
(superior iliac crest) with the patient standing.
Blood pressure was measured twice on the right upper 
arm in a sitting position using an automatic digital sphyg-
momanometer (Omron M6; OMRON Corporation, 
Kyoto, Japan) and the mean was used for the analyses.
Physical activity was assessed with the following ques-
tion: “Which of the following four alternatives describes 
your level of activity outside work in the best way?” (a) 
No physical activity weekly, (b) only light physical activ-
ity in most weeks, (c) vigorous physical activity at least 
20 min once or twice a week (d) vigorous physical activity 
for at least 20 min three or more times a week.
The FINDRISC [16] was integrated as a part of the 
interview conducted by the research staff. It includes 
eight questions/items (age, BMI, waist circumference, 
intake of fruit and vegetables, physical activity, high 
blood pressure, history of high glucose value and family 
history of diabetes). Depending on the response to each 
question a score is set, the sum of which allocates the 
responding person to one of the following categories: < 7 
low risk implying that 1 in 100 will develop T2DM within 
the next decade; 7–11 slightly elevated risk, 1 in 25 will 
develop T2DM; 12–14 moderate risk, 1 in 6 will develop 
T2DM; 15–20 high risk, 1 in 3 will develop T2DM; and 
> 20 very high, 1 in 2 will develop T2DM within the next 
decade. Applying a threshold of ≥ 9 revealed a sensitiv-
ity of 78%, a specificity of 77% and a predictive value of a 
negative test of 99% [3].
Laboratory investigations
Venous blood was drawn in the fasting state (≥  10  h) 
into a tube containing clot activator (Venosafe, Terumo 
Europe, Leuven, Belgium) for lipid assays and into a potas-
sium ethylenediaminetetraacetic acid (EDTA) tube for 
HbA1c assay. Total and high-density lipoprotein (HDL) 
cholesterol and triglycerides were analysed in serum and 
HbA1c in whole blood on a clinical chemistry analyzer 
(Abbot Architect analyzer; Abbott Laboratories, Abbott 
Park, Illinois, USA) at a central laboratory (Disease Risk 
Unit, National Institute for Health and Welfare, Helsinki, 
Finland) accredited by Finnish Accreditation Service ful-
filling the requirements of the standard SFS-EN ISO/IEC 
17025:2005. Total serum cholesterol was measured using 
an enzymatic and high-density cholesterol (HDL-C) with 
a homogenous method for direct measurement while tri-
glycerides were measured by an enzymatic glycerol phos-
phate oxidase method. Low-density lipoprotein (LDL-C) 
cholesterol was calculated according to Friedewald’s for-
mula [17]. Glycated HbA1c was analysed with an immu-
noturbidimetric method and expressed in mmol/mol 
according to IFCC and % according to Diabetes Control 
and Complications Trial (DCCT). The glomerular filtra-
tion rate (eGFR) was estimated from serum creatinine by 
Fig. 1 Patient flow chart
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means of the Chronic Kidney Disease Epidemiology Col-
laboration equation (CKD-EPI) [18].
The OGTT was performed using 75  g of anhydrous 
glucose in 200 ml of water in the morning after at least 
10 h of fasting. Blood for FPG was drawn before intake 
of the glucose with a dip safe from the EDTA-tube in 
which the HbA1c was collected. Samples for 2hPG were 
drawn from whole venous blood using an EDTA-tube. 
Plasma glucose was analysed locally with a photometric 
point-of-care technique (Glucose 201  +  ,  HemoCue®, 
Ängelholm, Sweden). Regression analysis between the 
 HemoCue® instrument, and standard isotope dilu-
tion gas chromatography–mass spectrometry (IDGC–
MS) showed a slope of 1.051 (95% confidence interval 
1.031–1.071) an intercept of − 0.222 (95% CI − 0.016 to 
− 0.428; r = 0.994). The mean deviation was 0.24 mmol/l 
(2.0%). Values obtained with the  HemoCue® instrument 
were in 69% within 5%, in 91% within 10%, and always 
within 14.3% of the IDGC–MS method [19]. Since the 
 HemoCue® method is cholesterol sensitive due to the 
measurement in very small volumes with higher lev-
els of glucose with low cholesterol the glucose values 
were corrected according to the formula:  HemoCue® 
glucose + 0.15  ×  (total cholesterol −  6). The values 
were converted from whole venous blood to plasma 
applying the formula by Carstensen et  al. [19]: plasma 
glucose = 0.558 + 1.119 × whole blood glucose. Stand-
ardized use of the equipment was ascertained through 
central training of the data collectors, and retrieval of 
 HemoCue®-cuvette storage information, and validation 
sheets from a selection of the participating centres.
Definitions
Hyperglycaemia defined as IFG, IGT, “high risk HbA1c” 
or newly detected T2DM was diagnosed according to 
WHO and ADA [20, 21] as outlined in Table 1.
Elevated LDL-C concentration was defined as a level 
≥ 2.5 mmol/l.
Normal kidney function was defined as eGFR ≥ 60 ml/
min/1.73 m2.
Overweight was defined as a body mass index (BMI) 
25.0–29.9 kg/m2 and obesity as a BMI ≥ 30 kg/m2. Cen-
tral obesity was defined as a waist circumference of 
≥ 88 cm for women and ≥ 102 cm for men [15].
Blood pressure was defined as elevated if systolic blood 
pressure (SBP) was ≥ 140 mmHg and/or diastolic blood 
pressure (DBP) ≥ 90 mmHg.
Smoking was defined as self-reported smoking or an 
exhaled carbon monoxide > 10 ppm [22].
The physical activity target was defined as vigorous 
physical activity outside work for ≥ 20 min at least once/
week.
The educational level was defined as low if only primary 
school or less had been completed.
Data management
The EURObservational Research Programme at the 
European Heart House (Nice, France) was in charge of 
data management. All data were collected electronically 
through web-based data entry using a unique identifica-
tion number for country, centre and individual. The data 
were submitted via the Internet to the data management 
centre where checks for completeness, internal consist-
ency and accuracy were performed. All data were stored 
under the provisions of the National Data Protection 
Regulations.
Statistical analyses
Continuous variables were summarised according to 
their mean and standard deviation (SD); dichotomous 
variables as percentages (n). For comparing character-
istics of included and excluded patients p-values were 
obtained from linear and logistic regression models 
adjusted for age and gender. All statistical analyses were 
undertaken using SAS statistical software (release 9.4) 
at the Department of Public Health, Ghent University, 
Belgium.
Results
Clinical characteristics
Pertinent clinical characteristics of included (n =  2395) 
and excluded (n = 817) patients are presented in Table 2; 
those excluded from the analysis were more often smok-
ers, less physically active and had a lower educational 
level, higher diastolic blood pressure, FPG and HbA1c 
Table 1 Definitions of dysglycaemia according to WHO 
and ADA
Test/diagnose Cut off level
HbA1c % DCCT mmol/mol IFCC
High risk HbA1c 5.7–6.4 39–47
Diabetes ≥ 6.5 ≥ 48
Plasma glucose mmol/l mg/dl
Impaired fasting glucose
 Fasting 6.1–6.9 110–125
 2 h postload < 11.0 < 200
Impaired glucose tolerance
 Fasting < 7.0 < 126
 2 h postload ≥ 7.8–11.0 ≥ 140–199
Diabetes
 Fasting > 7.0 > 126
 2 h postload ≥ 11.1 ≥ 200
Page 5 of 11Shahim et al. Cardiovasc Diabetol  (2018) 17:21 
and were more frequently using statins and calcium 
channel blockers. Among the included patients 94% had 
a normal kidney function and the eGFR was unrelated to 
FPG, 2 h-PG and HbA1c in all patients.
Glycaemic status
The distribution of T2DM by diagnostic test is pre-
sented in Fig. 2. A FPG alone identified 80% of those with 
previously unknown T2DM while FPG in combination 
with 2hPG identified 92% and FPG together with HbA1c 
90% of them.
A total of 455 patients (19%) were identified as having 
T2DM by the OGTT of whom 396 (87%) were detected 
by FPG alone. Including HbA1c ≥ 48 mmol/mol (DCCT 
≥  6.5%) as an additional diagnostic test the number of 
patients with newly detected T2DM increased by 13 to 
Table 2 Pertinent characteristics of included and excluded patients
Obesity-BMI ≥ 30 kg/m2
Central obesity-a waist circumference of ≥ 88 cm for women and ≥ 102 cm for men
Hypertension—systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg
Smoking—self-reported smoking or an exhaled carbon monoxide > 10 ppm
The physical activity target was defined as vigorous physical activity outside work for ≥ 20 min at least once/week
Low educational level—if completed only primary school or less
HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, ACEI angiotensin-converting enzyme inhibitor, AT-II angiotensin II receptor 
blockers, BMI body mass index
* Significance of the difference between groups, adjusted for age and gender; **N = 177; ****N = 167; ****N = 668
Variable Included (n = 2395) Excluded (n = 817) p value*
Age (years; mean ± SD) 58.1 (7.8) 57.9 (11.7) 0.71
Female gender (%, n) 60.8 (1457/2395) 57.8 (472/817) 0.13
BMI (kg/m2; mean ± SD) 29.4 (5.0) 29.3 (4.7) 0.38
Obesity (%, n) 40.8 (976/2395) 39.4 (318/808) 0.52
Central obesity (%, n) 60.7 (1452/2393) 60.6 (477/787) 0.81
Smoking
 Current (%, n) 16.0 (382/2395) 19.7 (161/817) 0.03
 Past (%, n) 26.2 (628/2395) 24.8 (203/817) 0.27
Hypertension (%, n) 49.1 (1175/2392) 52.1 (420/806) 0.19
Blood pressure (mmHg)
 Systolic (mean ± SD) 138.6 (17.9) 139.6 (18.3) 0.20
 Diastolic (mean ± SD) 82.8 (10.3) 84.5 (10.7) 0.0002
Blood lipids (mmol/l)
 Total cholesterol (mean ± SD) 5.63 (1.19) 5.60 (1.18) 0.63
 HDL cholesterol (mean ± SD) 1.31 (0.32) 1.30 (0.34) 0.29
 LDL cholesterol (mean ± SD) 3.58 (1.03) 3.54 (1.01) 0.52
 Triglycerides (mean ± SD) 1.66 (1.02) 1.73 (1.19) 0.56
Plasma glucose (mmol/l)
 Fasting (mean ± SD) 6.24 (0.91) 6.40 (0.83)** 0.02
 2 h postload (mean ± SD) 7.34 (2.28) 7.62 (2.26)*** 0.13
 HbA1c (%)(mean ± SD) 5.67 (0.50) 5.75 (0.67)**** 0.0003
Pharmacological treatment
 ASA/antiplatelets (%, n) 27.8 (665/2391) 25.0 (204/815) 0.14
 Lipid lowering (%, n) 31.0 (741/2391) 39.1 (318/814) < 0.0001
 Beta-blockers (%, n) 30.5 (730/2392) 31.5 (256/813) 0.53
 ACE-inhibitors (%, n) 48.2 (1153/2392) 49.0 (399/814) 0.71
 AT-II receptor blockers (%, n) 18.9 (452/2392) 19.8 (161/813) 0.56
 Calcium channel blockers (%, n) 22.4 (535/2392) 26.3 (214/814) 0.03
 Diuretics (%, n) 29.4 (703/2391) 31.5 (257/815) 0.21
 Low educational level (%, n) 10.5 (250/2382) 14.7 (120/816) 0.002
 Low or moderate physical activity (%, n) 55.4 (1295/2337) 61.5 (487/792) 0.001
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468 (19.5%). Eight percent of the patients were detected 
by all three tests. Patients who were detected as hav-
ing T2DM with HbA1c (8%) or 2hPG (10%) alone did 
not differ significantly from each other regarding age 
(mean ±  SD =  59.0 ±  10.3 vs. 61.5  ±  11.9; p =  0.21), 
gender (males = 55.3% vs. 65.3%; p = 0.17) or FINDRISC 
score (mean ± SD 12.6 ± 3.5 vs. 13.9 ± 4.0; p = 0.38).
The 2hPG revealed that another 479 patients (20%) 
had IGT. The FPG classified 1495/2395 patients (62%) as 
having IFG (FPG  =  5.6–6.9  mmol/l) including 395/479 
of the patients with IGT. A “high risk” HbA1c [IFCC 
39–47 mmol/mol (DCCT 5.7–6.4%)] was present in 72% 
of the total patient population.
Among the included patients 48.2–29.4% were treated 
with β-blockers or calcium channel blockers, respec-
tively. The prevalence of newly detected dysglycaemia 
among patients on β-blockers was 41.0% (299/730) 
and among those without β-blockers 38.2% (634/1662) 
(p  =  0.23 after adjustment for age and sex). About 
43.4% (232/535) of the patients treated with calcium 
channel blockers had dysglycaemia compared to 37.8% 
(701/1857) in patients not treated with calcium channel 
blockers (p = 0.11 after adjustment for age and sex). In 
patients treated with statins 35.9% (256/713) had newly 
detected dysglycaemia compared to 40.4% (677/1678) 
among those who were not treated with statins 
(p  =  0.0007 after adjustment for age and sex). Eighty-
five percent of the patients were Caucasians. Among the 
remaining 15% 173 were Asian of whom 53 (30.6%) had 
newly detected T2DM. The distribution of dysglycaemia 
according to the different screening tests was similar to 
that in the Caucasian population.
FINDRISC
The distribution of patients according to FINDRISC was: 
low risk to develop diabetes 10% (n = 244), slightly ele-
vated risk 36% (n = 857), moderate risk 29% (n = 686), 
high risk 23% (n = 549) and very high risk 3% (n = 59). 
The proportion of patients with T2DM detected by FPG, 
2hPG and HbA1c in relation to their FINDRISC category 
increased linearly (Fig. 3). The relationship between FIN-
DRISC category and dysglycaemia (T2DM and IGT com-
bined) diagnosed by FPG and 2hPG is shown in Fig. 4. Of 
patients, who according to FINDRISC had a low, mod-
erate/slightly elevated risk 20, 34 and 41% had IGT or 
T2DM respectively. The corresponding proportions for 
the high and very high-risk category were 49 and 71%.
Discussion
The main findings in this investigation of patients free 
from CVD but on treatment for hypertension and/or 
dyslipidaemia were that: (1) the prevalence of previously 
undetected dysglycaemia was very high; (2) a large pro-
portion of the present patient population in the lower 
FINDRISC categories for T2DM had dysglycaemia; (3) 
even if a FPG was the best single test for detecting T2DM 
it left a considerable proportion of patients with dysgly-
caemia undetected.
Dysglycaemia in the presence of other risk factors for CVD
The present data from a European primary care popu-
lation consolidate that dysglycaemia is a very common 
and global condition in patients with one or two other 
risk factors for CVD. The prevalence of screen detected 
dysglycaemia was 37% (IGT 11%; T2DM 17%) in the 
Impaired Glucose Tolerance and Long-Term Outcomes 
Observational (IGLOO) study, based on 1377 Mediter-
ranean participants without known CVD but with one or 
more cardiovascular risk factors [23]. A similar propor-
tion, 41%, was reported by the ARIC study [24] screen-
ing 8286 middle-aged American participants with the 
OGTT, of whom many with hypertension, dyslipidaemia 
and/or central obesity. Further, 14% had screen detected 
T2DM in a cross-sectional population-based study from 
Kuwait in which more than half of the participants were 
overweight or obese but without any history of CVD [25].
In the Interventions in Europe and Worldwide (PRE-
VIEW) among 424 New Zealanders with overweight 
and FINDRISC score of ≥ 12, about 65% had undetected 
prediabetes and 7% T2DM when screened with the 
OGTT [26]. A higher FINDRISC score was significantly 
associated with prediabetes and T2DM (p =  0.02). The 
prevalence of dysglycaemia among those with lower FIN-
DRISC score was, however, not investigated.
59%
8%
10%9%
2%
8%
4%
FPG + HbA1c (90%)
FPG + 2hPG = OGTT (92%)
2hPG (29%)
HbA1c (22%)
FPG (80%)
Fig. 2 The 492 patients with newly detected T2DM. Propor-
tions and their overlap between screening with FPG ≥ 7 mmol/l, 
2hPG ≥ 11.1 mmol/l, HbA1c ≥ 6.5%/48 mmol/mol and combinations 
commonly used in clinical practice (FPG + HbA1c and FPG + 2 hPG)
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The importance of dysglycaemia screening
It has since long been established that dysglycaemia is an 
important risk factor for future CVD [2]. Other impor-
tant risk factors for CVD are dyslipidaemia and hyper-
tension in the presence of which dysglycaemia causes a 
dramatic increase in the risk for future CVD [27, 28]. The 
outcome of dysglycaemia screening is therefore a pre-
requisite for the institution of a multifactorial risk factor 
management as strongly emphasized by contemporary 
guidelines for cardiovascular disease prevention [2, 29]. 
It may be argued that patients under treatment for hyper-
tension and/or hyperlipidaemia should have received 
life-style advice, the corner-stone in dysglycaemia man-
agement. Still 40% had undetected T2DM or IGT indi-
cating a need for intensified life-style advice most likely 
supplemented by glucose lowering drugs in patients with 
newly detected T2DM. As regards IGT the experiences 
from the Da Qing study (11) and the Finnish diabetes 
prevention study [30] demonstrate that an improved 
life-style significantly reduced the development of overt 
T2DM during prolonged periods of follow up. Moreover, 
micro- and macro-vascular complications including car-
diovascular mortality was reduced in the Da Qing study.
Opportunistic screening for dysglycaemia, as applied 
in the present study, is not contradicted by the ongoing 
debate on the value of population based screening for 
diabetes based on the inconclusive results of The Anglo–
Danish–Dutch Study of Intensive Treatment in People 
with Screen-Detected Diabetes in Primary Care (ADDI-
TION) [31–34]. A reasonable assumption is that ADDI-
TION, testing a community based screening programme 
in a general population, does not reflect the benefit of 
screening for dysglycaemia in a population at higher risk 
due to already diagnosed risk factors. In such population, 
an early instituted and comprehensive treatment has a 
more obvious rationale. A remaining question is how to 
screen. The willingness is by apparent reasons dependent 
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Fig. 3 Proportion of patients with newly detected T2DM by either FPG, 2hPG or HbA1c in each of the FINDRISC categories. The total numbers of 
patients in each FINDRISC category are indicated below each bar
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of screening tools that are easy to handle and affordable. 
The simplicity of the FINDRISC questionnaire makes it 
easy to apply for the initiation of primary prevention in 
high risk people [13, 35]. In addition it is valuable for the 
detection of IGT, relates to markers of insulin resistance 
[36] and predicts CVD events and mortality [37].
FINDRISC in relation to blood glucose measurements
In the present investigation it was hypothesized that the 
use of FINDRISC as a first step in dysglycaemia screening 
would reduce the need for blood tests. This assumption 
could not be verified since a large proportion (20–40%) 
of the participants were dysglycaemic already in the 
low-moderate FINDRISC risk categories. The most rea-
sonable explanation is the high overall prevalence of dys-
glycaemia in the present population of people treated 
for—hypertension and/or dyslipidaemia. FINDRISC 
was based on a sample derived from the general popula-
tion and its discriminatory ability is reported to be less 
in populations at higher risk [38]. Furthermore, the dif-
ferent FINDRISC components may differ by race and 
gender as reported by a subset of the ARIC study [39]. 
For example, waist circumference was more predictive 
of incident diabetes than BMI among black men but not 
in white women. An alternative to the FINDRISC for the 
prediction of dysglycaemia may to estimate lipoprotein 
(a), triglyceride/HDL-C ratio and triglyceride glucose 
index, which has been associated with insulin resistance 
and the risk of future incident diabetes [40–42].
Several studies added biochemical measures, in par-
ticular FPG to improve the predictive capacity of risk 
scoring models [43]. Thus, screening was based on the 
IFG cut point (≥ 6.1 mmol/l) in the ARIC study to be fol-
lowed by a clinical detection rule based on the risk fac-
tors of the metabolic syndrome and CVD for those below 
this value. With this strategy 86% of those with T2DM 
and 66% of all hyperglycaemia cases were detected, 
identifying 42% of the study population as screen posi-
tive [24]. In the IGLOO study, addressing opportunistic 
screening strategies based on the FINDRISC in individu-
als with one or more cardiovascular risk factors, the best 
screening strategy seemed to be based on FPG measure-
ment in all participants and the performance of OGTT 
only in those with a FPG ≥ 5.6 mmol/l [23]. Based on this 
strategy, in which an OGTT was required for 56% of the 
studied population, 97% of the participants with T2DM 
and 78% of those with IGT was identified.
In the present study, the combination of FPG and 
2hPG identified 92% of those with T2DM and the 2hPG 
another 20% with IGT. The superiority of this combina-
tion corresponds to the outcome of a previous study from 
EUROASPIRE IV on glycaemic screening of patients 
with established coronary artery disease [44] and in a 
recent population based study population consisting of 
overweight and obese subjects free from cardiovascular 
disease [45]. “High risk” HbA1c [DCCT 5.7–6.4% (IFCC 
39–47 mmol/mol)] classified a majority (72%) of the pre-
sent population as having glucose perturbations. This 
proportion is reasonably too high. Furthermore “high 
risk” HbA1c is less sensitive than IFG and IGT to detect 
individuals with insulin resistance and ß-cell dysfunc-
tion [46]. According to a WHO expert group, “high risk” 
HbA1c is a less effective diagnostic tool than FPG and 
2hPG and current evidence is insufficient to make any 
formal recommendation on the interpretation of HbA1c 
levels < 6.5% [20, 47].
An alternative, limiting OGTT to 62% of the popula-
tion (those with IFG), would be to start screening with a 
FPG continuing with an OGTT only in patients not ful-
filling the criteria for T2DM. With such strategy 18% of 
patients with IGT would be missed. It has to be debated 
whether this is acceptable.
Strengths and limitations
A major strength of EUROASPIRE IV is that data are 
based on interviews and standardised examinations of a 
large cross-sectional European population of well-char-
acterised high-risk patients treated for hypertension and/
or dyslipidaemia. Thus, the studied population is repre-
sentative for a common at-risk group which, so far free 
from CVD, should be of particular interest for targeted 
life-style based interventions [4, 5, 48]. All tests (FPG, 
2hPG and HbA1c) were uniformly undertaken by cen-
trally trained staff members using the same methodology 
including a central laboratory. A limitation is that, as in 
almost all similar studies, dysglycaemia was based on a 
single glucose recording rather than, as recommended by 
WHO for a clinical diagnosis, repeated measurements. 
Moreover, it may be argued that patients who, due to 
missing data, were excluded had a somewhat higher risk 
profile (Table 2). This may, if of any importance, contrib-
ute to an underestimation of the true prevalence of dys-
glycaemia. Markers of dysglycaemia may vary by race and 
ethnicity [49, 50]. The vast majority of the present popu-
lation was of Caucasian origin limiting the generalisabil-
ity of the present findings to such populations.
Statin use may increase the risk for T2DM as well as 
β-blockers and possibly calcium channel blockers [51]. 
In the present study patients on statins had a lower pro-
portion of dysglycaemia and there were no significant 
differences for β-blockers or calcium channel blockers. 
These data, derived from a cross-sectional investigation, 
should be looked at as descriptive for the present patient 
population. Accurate information on drug induced dys-
glycaemia can only be derived from longitudinal (cohort) 
studies. In contrast, the aim of the present study was to 
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screen for undetected dysglycaemia in the presence of 
other risk factors and not to outline the risk for pharma-
cologically induced dysglycaemia.
It has been claimed that an OGTT has a limited repro-
ducibility in particular for establishing the presence 
of IGT [52]. In a study by Wallander et al. [53] patients 
were screened with OGTT 5 days, 3 and 12 months after 
an AMI. Of those who were identified to have dysgly-
caemia at hospital discharge 93% were still classified as 
such, either having diabetes (64%) or IGT (29%) after 
12  months. Of patients with IGT at hospital discharge 
71% hade IGT or diabetes 12 months later and 29% nor-
mal glucose metabolism while 60% of patients classified 
with normal glucose metabolism at discharge remained 
normal after 12  months and 40% had developed IGT 
or type 2 diabetes. Thus, an OGTT seems to be reliable 
enough for screening purpose. Still, a second test should 
be performed to confirm the diagnosis, as recommended 
by WHO, before the institution of treatment.
Conclusions
Hidden dysglycaemia is very common in patients treated 
for hypertension and/or dyslipidaemia. To apply FIND-
RISC as a first step of dysglycaemia screening does not 
provide any benefit in such populations. Of different 
blood tests a single HbA1c was the least efficient due 
to its limited ability to detect T2DM and its inability to 
diagnose IGT. The combination of FPG and 2hPG was 
the best test for detecting T2DM and the FPG was the 
single best test. The latter is, however, limited by the 
inability to detect IGT. A pragmatic strategy, decreasing 
the demand for an OGTT by 21%, would be to screen all 
patients with FPG followed by OGTT in patients with 
IFG. Finding simpler methods e.g. based on a 1 hour post 
load glucose [54] to identify individuals at high risk of 
progression to diabetes and CVD in the need for more 
targeted prevention strategies remains an important goal.
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